Enrique Gonzalez Billalabeitia - European Medicines Agency

Curriculum Vitae
PERSONAL INFORMATION
Enrique Gonzalez Billalabeitia
WORK EXPERIENCE
July 2003 – Present
Staff
Hospital Universitario Morales Meseguer, (Spain)
Medical oncologist
July 2003 – Present
Assistant Professor.
Universidad de Murcia, (Spain)
Department of Medicine
February 2013 – September 2013
Associate Professor
Universidad de Murcia, (Spain)
Biochemistry and molecular biology
EDUCATION AND TRAINING
September 1992 – June 1998
Medical Degree
Universidad de Navarra, (Spain)
Medical Degree (M.D.)
May 1999 – June 2003
Medical Oncology Specialist
Hospital 12 de Octubre. Madrid, (Spain)
Medical Oncologist
April 2001 – November 2006
PhD in Medicine
Universidad Complutense de Madrid, (Spain)
July 2006 – December 2008
Postgraduate studies in Statistics and Health Science
Universidad Autónoma de Barcelona, (Spain)
September 2010 – August 2012
Post-doctoral fellowship in genetics
Harvard University, (Spain)
Pandolfi Laboratory. Prostate cancer animal models and translation.
ADDITIONAL INFORMATION
Expertise
Publications
Medical oncology. Urological tumors. Molecular biology
Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia, E, Egia A,
Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald
WL, Pandolfi PP. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent
pathway for cellular
© European Union, 2002-2013 | http://europass.cedefop.europa.eu
Page 1 / 2
Curriculum Vitae
Enrique Gonzalez Billalabeitia
senescence bypass and tumor invasion. Nature Genetics 2013 (advanced online publication)
doi:10.1038/ng.2654.
Vicente Conesa M. A. , García-Martinez M.E., González-Billalabeitia E. et al.
Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary
chemotherapy. Breast 2012; 21: 468-74.
Carmona-Bayonas A., Gomez J., González-Billalabeitia E., et al. Prognostic evaluation of febrile
neutropenia in apparently stable adult
cancer patients. Br J Cancer 2011;105: 612–617.
Gonzalez-Billalabeitia E., Calzas J., Castellano D., et al. Long-term follow-up of an anthracyclinecontaining metronomic chemotherapy schedule in advanced breast cancer. Breast J 2009; 15: 551–
553.
Gonzalez-Billalabeitia E, Quintela-Fandino M, Alemany I, López-Alonso
G, Ruiz-Ollero A, Martinez-Tello F, Hitt R. Coexistence of two rare sarcomas: primary leiomyosarcoma
of bone and epithelioid hemangioendothelioma of the liver. Sarcoma 2008;2008:416085.
González-Billalabeitia E, Hitt R, Fernández J, Conde E, Martínez-Tello F,
Enríquez de Salamanca R, Cortés-Funes H. Pre-treatment serum lactate dehydrogenase level is an
important prognostic factor in high-grade extremity osteosarcoma. Clin Transl Onco 2009
Jul;11(7):479-83.
Zafra M, Ayala F, Gonzalez-Billalabeitia E, Vicente E, Gonzalez-Cabezas P,
García T, Macías JA, Vicente V. Impact of whole body FDG-PET on diagnostic and therapeutic
management. Eur J Cancer 2008; 44:1678--1683.
Osma MM, González-Billalabeitia E, Ortuño F. Transient massive peripheral blood elastosis in patient
with renal clear cell carcinoma alter treatment with high-dose recombinant inteleuklin-2. Lancet Oncol
2007;8:275-6.
Quintela-Fandino M, Gravalos C, González E, García-Velasco A, CortesFunes H. Irinotecan (CPT-11) based chemotherapy as induction treatment for
advanced colorectal cancer. Anticancer Drugs 2005; 16:31-38.
Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E,
Hernando S, Hernandez R, Sanchez-Muñoz A, Lopez-Martin A, Duran I, Robles L,
Cortés-Funes H, Paz-Ares L. Assessment of procalcitonin as a diagnostic and prognostic marker in
patients with solid tumors and febrile neutropenia. Cancer 2004; 100(11): 2462-9.
A. Sánchez-Muñoz, Lopez Medrano F, Artiles Valle V, Jimeno Largo A, E.
González Billalabeitia. Isquemia intestinal extensa en un paciente con cáncer de colon con
recurrencia locoregional. Revista Clínica Española 2003;203(10):489-90.
E. González Billalabeitia, A. Jimeno, A. García Velasco, E. Ciruelos. Cáncer de próstata. Chapter
book. Oncología Médica en atención primaria. Ed. Nova Sidonia Oncología y Hematología, 2003.
H.Cortés-Funes y E. González Billalabeitia. Efecto antiangiogénico de la quimioterapia citotóxica.
Angiogénesis tumoral y sus implicaciones en el tratamiento médico del cáncer. Chapter book. You &
US S.A. 2002; pag 67-74.
Projects
Memberships
Papel del cluster miR-17-92 en la angiogénesis del cáncer de mama Proyecto FIS. ISCIII.
PI12/02877. Investigador colaborador INICIO/ FINALIZACIÓN Octubre-2012 a Octubre 2015. PI:
Francisco Ayala de la Peña. Colaborators: E.González Billalabeitia, Gloria Soler Sánchez,
AsunciónChaves, Rocío González-Conejero.
Papel de los micro-RNAs en la angiogénesis del cáncer de mama y en la respuesta angiogénica a la
quimioterapia. Fundación Salud 2000. 2012-2014. PI: Francisco Ayala de la Peña. Colaborator. E.
González-Billalabeitia, G. Soler Sánchez, T. García García, A. Chaves Benito, G. Luengo Gil
Estudio co-clínico en el cancer de próstata. BAE. Instituto de salud carlos III (10BA/00031). Estancia
Postdoctoral en la Universidad de Harvard. Sept-2010 a Agosto 2012. IP: Enrique González
Billalabeitia
SEOM (Spanish Society of Medical Oncology) 2003-2013
ESMO (European Society for Medical Oncology) 2003-2011
ASCO (American Society for medical Oncology) 2003-2011
Other Relevant Information
© European Union, 2002-2013 | http://europass.cedefop.europa.eu
Page 2 / 2